Clinical research of DC-CIK on regulating cellular immune in patients with diffuse large B cell lymphoma

Objective To investigate the effect of autologous dendritic cells and cytokine-induced killer cells transfusion therapy on the improvement of immune function in patients with diffuse large B-cell lymphoma (DLBCL). Methods Total 23 cases of diffuse large B-cell lymphoma confirmed by histological and immunohistochemical were selected from Nanyang First People Hospital during April 2012 to April 2015. All of the patients attained to at least partial remission. Peripheral blood mononuclear cells were isolated by Cobe Spectra blood cell separator, and induced into DC-CIK cells by conventional methods. DC-CIK cells were intravenous injected into patients twice every 15 days, a total of 4 times. The changes of absolute lymphocyte count were detected by hematology analyzer and peripheral lymphocyte subsets were detected by flow cytometry. The levels of INF-γ, IL-2 in serum were detected by Elisa. Meanwhile, the adverse reactions were observed. Results After 4 times DC-CIK cells transfusion therapy, the level of ALC [ (2.17±1.58)×10⁹/L] were significantly higher than those before treatment level [(0.83±0.79)×10⁹/L], P<0.05. The ratio of Treg cell was significant decreased [(4.92±2.38)% vs. (6.01±2.07)%], P<0.05. It was found that numerical value of T, Th, Ts, CD3⁺ T, CD3⁺CD4⁺ T, CD3⁺CD8⁺ T, NK cell, IL-2 and INF-γ was not statistically difference before and after treatment (P>0.05). Conclusion Autologous DC-CIK cell immunotherapy can improve the DLBCL patients' cellular immune function by improving ALC and reducing Treg.